Top > Search of International Patents > CELL FOR PRODUCING INFLUENZA VIRUS, AND METHOD FOR PRODUCING INFLUENZA VIRUS

CELL FOR PRODUCING INFLUENZA VIRUS, AND METHOD FOR PRODUCING INFLUENZA VIRUS meetings

Foreign code F160008788
File No. (E096P08)
Posted date Aug 4, 2016
Country WIPO
International application number 2015JP076681
International publication number WO 2016047595
Date of international filing Sep 18, 2015
Date of international publication Mar 31, 2016
Priority data
  • P2014-192753 (Sep 22, 2014) JP
Title CELL FOR PRODUCING INFLUENZA VIRUS, AND METHOD FOR PRODUCING INFLUENZA VIRUS meetings
Abstract Provided are a cell that can be cultured in vitro , said cell being highly capable of proliferating an influenza virus and appropriately usable for the production of the influenza virus for manufacturing a vaccine, and a method for producing the influenza virus using the aforesaid cell. The cell for producing an influenza virus according to the present invention is characterized in that the expression of at least one gene encoding a protein that participates in an effect of inhibiting the production of the influenza virus in cells is inhibited, said gene(s) being selected from a group consisting of ACTG1 gene, etc. The method for producing an influenza virus according to the present invention is characterized by comprising infecting the aforesaid cell for producing an influenza virus with the influenza virus and then culturing the cell.
Outline of related art and contending technology BACKGROUND ART
The influenza virus can be, cause epidemics every year, several million when the victim issues cause pandemics. Is in the prevention of influenza infection, mainly, performed by the vaccination of the vaccine. Vaccine, influenza virus particles or a portion thereof is inactivation of the decomposition product of the present invention. By vaccination of the influenza vaccine, when afflicted with influenza, such as appearance and serious complications such as pneumonia, hospitalization, or reducing the risk of death.
The vaccine of the current, the influenza virus in embryonated chicken eggs produced by the inoculation. For this reason, a large amount of production of the vaccine need to be secured in an embryonated chicken egg. In addition, since the manufacture of 6 take months, sudden vaccine mass production is difficult. In addition, the egg component needs to be considered for allergic reaction.
Further, in the case of increasing the number of influenza virus in the chicken egg, by that mutation virus, antigens of a virus is often changed. Actually, in recent years for the type of vaccine B type H3N2, antigenicity of the vaccine strains selected, does not coincide with the clade despite the fact that, at the manufacturing stage vaccine virus enters a mutation of the gene, produced the original antigenicity has changed from the vaccine strain. Therefore, 'therein each pandemic strains despite the fact that the prediction, a weak vaccine effect' due to the fact that the (see non-patent document 1.).
Scope of claims (In Japanese)[請求項1]
染色体中の一部の遺伝子の発現が抑制されている、生体外で培養可能な細胞であり、
前記遺伝子が、ACTG1遺伝子、ACTN1遺伝子、ATCAY遺伝子、CCT6A遺伝子、COPS7B遺伝子、DAP3遺伝子、ERLIN2遺伝子、GNAI2遺伝子、GTF3C5遺伝子、HNRPAB遺伝子、KHSRP遺伝子、KRT18遺伝子、MTCH1遺伝子、PPP2R1A遺伝子、PRPS1遺伝子、RAB18遺伝子、RAB3A遺伝子、RAP1B遺伝子、RPS19遺伝子、RPS7遺伝子、S100A10遺伝子、SFRS7遺伝子、SLC2A12遺伝子、TMED2遺伝子、及びUSP10遺伝子からなる群より選択される1以上の遺伝子であることを特徴とする、インフルエンザウイルス産生用細胞。
[請求項2]
前記遺伝子が欠損又は破壊されている、請求項1に記載のインフルエンザウイルス産生用細胞。
[請求項3]
前記遺伝子が、ACTG1遺伝子、ACTN1遺伝子、DAP3遺伝子、GNAI2遺伝子、GTF3C5遺伝子、KRT18遺伝子、MTCH1遺伝子、PRPS1遺伝子、RPS19遺伝子、S100A10遺伝子、SFRS7遺伝子、SLC2A12遺伝子、USP10遺伝子、PPP2R1A遺伝子、及びTMED2遺伝子からなる群より選択される1以上である、請求項1又は2に記載のインフルエンザウイルス産生用細胞。
[請求項4]
哺乳類由来の細胞である、請求項1~3のいずれか一項に記載のインフルエンザウイルス産生用細胞。
[請求項5]
ヒト由来の細胞である、請求項4に記載のインフルエンザウイルス産生用細胞。
[請求項6]
腎臓由来の細胞である、請求項4に記載のインフルエンザウイルス産生用細胞。
[請求項7]
インフルエンザウイルスワクチンの製造に用いられる、請求項1~6のいずれか一項に記載のインフルエンザウイルス産生用細胞。
[請求項8]
請求項1~7のいずれか一項に記載のインフルエンザウイルス産生用細胞に、インフルエンザウイルスを感染させた後、培養することを特徴とする、インフルエンザウイルスの産生方法。
[請求項9]
前記インフルエンザウイルスが、インフルエンザウイルスワクチンを製造するためのインフルエンザウイルスである、請求項8に記載のインフルエンザウイルスの産生方法。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • Inventor
  • KAWAOKA Yoshihiro
  • WATANABE Tokiko
  • KAWAKAMI Eiryo
  • WATANABE Shinji
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Reference ( R and D project ) ERATO KAWAOKA Infection-induced Host Responses AREA
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close